Max Rosett
Directeur Financier/CFO chez IMMUNOME, INC.
Fortune : 283 147 $ au 30/04/2024
Postes actifs de Max Rosett
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMMUNOME, INC. | Comptroller/Controller/Auditor | 10/05/2024 | - |
| Directeur des opérations | 02/10/2023 | - | |
| Directeur Financier/CFO | 02/01/2024 | - | |
| Investor Relations Contact | 02/10/2023 | - |
Historique de carrière de Max Rosett
Anciens postes connus de Max Rosett
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Research Bridge Partners /Venture Capital/
 Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Corporate Officer/Principal | - | 01/11/2023 |
MorphImmune, Inc.
 MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Directeur des opérations | 01/03/2022 | 01/10/2023 |
| Corporate Officer/Principal | 01/01/2022 | 01/03/2022 |
Formation de Max Rosett
| Yale University | Undergraduate Degree |
| Georgia Institute of Technology | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 6 |
Opérationnelle
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
MorphImmune, Inc.
MorphImmune, Inc. BiotechnologyHealth Technology MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. | Health Technology |
Research Bridge Partners /Venture Capital/
Research Bridge Partners /Venture Capital/ Investment ManagersFinance Research Bridge Partners (Research Bridge Partners) is a venture capital firm founded in 2016 by Reid Hoffman. The firm is headquartered in Austin, Texas. | Finance |
- Bourse
- Insiders
- Max Rosett
- Expérience